CRYDIS project

Driving innovation in pharmaceuticals: integrated studies of physical dissolution properties of crystalline and amorphous forms using enhanced orthogonal monitoring techniques.

CRYDIS project curve


CRYDIS undertakes innovative, collaborative research on the clinically-important topic of dissolution of drug substance particles in bio-relevant media and the undesired subsequent nucleation and re-precipitation of the drug prior to its absorption.
Using innovative advances in UV imaging technology, CRYDIS investigates the utility of novel dissolution assays as key tools to obtain fundamental data on the mechanism and kinetics of undesired nucleation and re-precipitation during or following dissolution, a significant problem for the pharmaceutical industry which struggles to obtain sufficient exposure to poorly soluble drug substances to ensure an effective dose is absorbed by the patient.
The key technologies in this project offer a step change in capability and functionality, offering the potential to undertake more detailed studies of the dissolution/re-precipitation processes relevant to pharmaceutical materials. Access to this key technology and the further development of its capability offers the potential for breakthroughs in development of process understanding and of robust and widely applicable protocols, thus, on a longer term perspective contributing to faster translation of molecules to medicines to patients.

CRYDIS partners

  • Paraytec Ltd, York, UK
  • Pfizer Ltd, Sandwich, UK
  • Sirius Analytical Ltd, Forest Row, UK
  • University College Cork, Cork, Ireland
  • University of Copenhagen, Copenhagen, Denmark


CRYDIS is a Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) project under the European Union´s Horizon 2020 programme running from January 2015 through December 2017. The CRYDIS exchange programme will establish and support international and inter-sectoral transfer of knowledge and expertise in pharmaceutical and instrument science between several EU research institutes and industrial companies. The project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 644056.

For further information please contact project coordinator Associate Professor Jesper Østergaard, Department of Pharmacy, University of Copenhagen, e-mail:

European Commission Logo








Activities and Output


Application of UV imaging in formulation development.
Sun, Yu; Østergaard, Jesper.
I: Pharmaceutical Research, Bind 34, Nr. 5, 2017, s. 929–940. 

Performance characteristics of UV imaging instrumentation for diffusion, dissolution and release testing studies.
Jensen, Sabrine S; Jensen, Henrik; Goodall, David M; Østergaard, Jesper.
In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 131, 30.11.2016, p. 113-123.


Surface Dissolution Imaging Workshop: Introduction to UV imaging for drug dissolution and release testing.
June 8-10, 2015. Department of Pharmacy, University of Copenhagen